Short-term heparin kinetics during Catheter ablation of atrial fibrillation

PACE - Pacing and Clinical Electrophysiology

Volumn 38, Issue 10, 2015, Pages 1142-1150

  Gabus, Vincent ^a   Rollin, Anne ^b   Maury, Philippe ^b   Forclaz, Andrei ^a   Pascale, Patrizio ^a   Dhutia, Harshil ^c   Bisch, Laurence ^a   Pruvot, Etienne ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b CHU RANGUEIL   (France)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

anticoagulation; atrial fibrillation; catheter ablation; thromboembolism; unfractionated heparin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; ENOXAPARIN; HEPARIN; PHYTOMENADIONE; ANTICOAGULANT AGENT;

ACTIVATED CLOTTING TIME; ADULT; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLOOD CLOTTING TIME; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE ASSESSMENT; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CONGESTIVE CARDIOMYOPATHY; CREATININE BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAROXYSMAL ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PULMONARY VEIN ISOLATION; THROMBOCYTE COUNT; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREND STUDY; ADVERSE EFFECTS; BIOAVAILABILITY; BLOOD; BLOOD CLOTTING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; KINETICS; METABOLIC CLEARANCE RATE; PROCEDURES; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL AVAILABILITY; BLOOD COAGULATION; CATHETER ABLATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN; HUMANS; KINETICS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; THROMBOEMBOLISM; TREATMENT OUTCOME; WHOLE BLOOD COAGULATION TIME;

EID: 84942988659     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12667     Document Type: Article

References (21)

1. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen S-A, Crijns HJG, et al., HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14: 528-606.
2. Wazni OM, Rossillo A, Marrouche NF, Saad EB, Martin DO, Bhargava M, Bash D, et al., Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: Impact of different anticoagulation regimens and importance of intracardiac echo imaging. J Cardiovasc Electrophysiol 2005; 16: 576-581.
3. Cappato R, Calkins H, Chen S-A, Davies W, Iesaka Y, Kalman J, Kim Y-H, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005; 111: 1100-1105.
4. Cappato R, Calkins H, Chen S-A, Davies W, Iesaka Y, Kalman J, Kim Y-H, et al., Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-38.
5. Gaita F, Caponi D, Pianelli M, Scaglione M, Toso E, Cesarani F, Boffano C, et al., Radiofrequency catheter ablation of atrial fibrillation: A cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 2010; 122: 1667-1673.
6. Lakkireddy D, Reddy YM, Biase L Di, Vanga SR, Santangeli P, Swarup V, Pimentel R, et al., Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2012; 59: 1168-1174.
7. Di Biase L, Gaita F, Toso E, Santangeli P, Mohanty P, Rutledge N, Yan X, et al., Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm 2014; 11: 791-798.
8. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Lakkireddy D, et al., Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 2010; 121: 2550-2556.
9. Lakkireddy D, Reddy YM, Biase L Di, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, et al., Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2014; 63: 982-988.
10. Bruce CJ, Friedman PA, Narayan O, Munger TM, Hammill SC, Packer DL, Asirvatham SJ, et al., Early heparinization decreases the incidence of left atrial thrombi detected by intracardiac echocardiography during radiofrequency ablation for atrial fibrillation. J Interv Card Electrophysiol 2008; 22: 211-219.
11. Konduru SV, Cheema AA, Jones P, Li Y, Ramza B, Wimmer AP,. Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran versus patients on uninterrupted warfarin. J Interv Card Electrophysiol 2012; 35: 277-284.
12. Bloemen S, Hemker HC, Dieri R Al,. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica 2013; 98: 549-554.
13. Calkins H, Brugada J, Packer DL, Cappato R, Chen S-A, Crijns HJG, Damiano RJ, et al., HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures, and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); In collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Europace 2007; 9: 335-379.
14. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, et al., ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
15. Tse H-F, Kwong Y-L, Lau C-P. Transvenous cryoablation reduces platelet activation during pulmonary vein ablation compared with radiofrequency energy in patients with atrial fibrillation. J Cardiovasc Electrophysiol 2005; 16: 1064-1070.
16. Wijns W, Kolh P, Danchin N, Mario C Di, Falk V, Folliguet T, Garg S, et al., Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.
17. Narins CR, Hillegass WB, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, et al., Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996; 93: 667-671.
18. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR,. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994; 23: 1061-1065.
19. Hattersley PG,. Activated coagulation time of whole blood. JAMA 1966; 196: 436-440.
20. Bosch YPJ, Weerwind PW, Nelemans PJ, Maessen JG, Mochtar B,. An evaluation of factors affecting activated coagulation time. J Cardiothorac Vasc Anesth 2012; 26: 563-568.
21. Fevold RT, Leung YT, Garofoli AC, White RD, Barsness GW, Dierkhising RA, Ou NN,. Heparin dose adjustment required to maintain goal-activated partial thromboplastin time during therapeutic hypothermia. J Crit Care 2015; 30: 574-578.